CloudMD Software & Services Inc. to Post Q1 2022 Earnings of ($0.02) Per Share, Echelon Wealth Partners Forecasts (CVE:DOC)

CloudMD Software & Services Inc. (CVE:DOCGet Rating) – Equities research analysts at Echelon Wealth Partners issued their Q1 2022 earnings per share estimates for shares of CloudMD Software & Services in a report released on Wednesday, May 4th. Echelon Wealth Partners analyst R. Goff anticipates that the company will earn ($0.02) per share for the quarter. Echelon Wealth Partners has a “Speculative Buy” rating on the stock. Echelon Wealth Partners also issued estimates for CloudMD Software & Services’ Q2 2022 earnings at ($0.02) EPS, Q3 2022 earnings at ($0.02) EPS and Q4 2022 earnings at ($0.01) EPS.

Separately, Canaccord Genuity Group reduced their price target on CloudMD Software & Services from C$3.00 to C$1.50 in a research report on Wednesday.

DOC stock opened at C$0.49 on Thursday. The business has a 50-day moving average of C$0.70 and a 200-day moving average of C$0.96. CloudMD Software & Services has a fifty-two week low of C$0.48 and a fifty-two week high of C$2.35. The company has a debt-to-equity ratio of 15.86, a current ratio of 1.65 and a quick ratio of 1.52. The stock has a market capitalization of C$140.97 million and a P/E ratio of -4.50.

About CloudMD Software & Services (Get Rating)

CloudMD Software & Services Inc, a healthcare technology company, provides SaaS based health technology solutions to medical clinics in North America. It offers CloudMD telemedicine application, a telemedicine platform that connects patients to licensed physician through videoconferencing technology; operates a network of inter-connected medical clinics; and Re:Function, an integrated network of 8 rehabilitation clinics that offers various rehabilitation services.

Read More

Receive News & Ratings for CloudMD Software & Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CloudMD Software & Services and related companies with MarketBeat.com's FREE daily email newsletter.